Compare NCTY & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCTY | RANI |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.6M | 134.6M |
| IPO Year | 2004 | 2021 |
| Metric | NCTY | RANI |
|---|---|---|
| Price | $7.30 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 38.2K | ★ 2.6M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,403,864.00 | $1,200,000.00 |
| Revenue This Year | N/A | $414.59 |
| Revenue Next Year | N/A | $30.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.95 | $0.39 |
| 52 Week High | $17.83 | $3.87 |
| Indicator | NCTY | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 42.77 | 42.10 |
| Support Level | $6.58 | $1.40 |
| Resistance Level | $8.31 | $1.53 |
| Average True Range (ATR) | 0.60 | 0.11 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 24.28 | 15.00 |
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.